Ep192: Kate Haviland on Following the Science to Precision Immunology
Podcast: The Long Run with Luke TimmermanPublished On: Thu Jan 08 2026
Description: Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
The note was deleted
The note was saved
Your message was sent